James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleWorkday, GitLab, and Figma have each moved off pure per-seat pricing and onto meters that charge for completed work. The market rewarded the companies that kept the most seat-like structure and punished the meters, and August's whipsaw is the gap between the two.
Unitree Robotics closed its Shanghai debut up 460 percent, at roughly 1,200 times earnings. That multiple isn't a price on Unitree's business, it's a price on Tesla's Optimus story, denominated in a different company's stock.
The Treasury doubled its debt buyback size after the 30-year yield hit a two-decade high. The purchase itself is a rounding error against $32 trillion in debt, so the market's rally was a response to the message, not the money.
A former Veritex executive is rolling up small Texas community banks. Of six banks that fit his criteria, three never returned his call. The constraint on the deal flow isn't capital, it's the owners' retirement calendar.
Moderna and Merck's personalized mRNA vaccine slowed melanoma's return in a phase 3 trial, but each dose is built from a specific patient's tumor and can't be made until weeks after surgery. That wait is part of the medicine, not a footnote.
Google outbid an AI data company for Spirit Airlines' internal business archive, 100 million emails and more, stripped of passenger data. The sale reveals a structural quirk: complete corporate archives only reach the market after the company dies.
Diesel hit a record August average while gasoline stayed comparatively contained. The reason is that diesel is the world's most globally traded fuel, the U.S. is now its marginal supplier, and the world's shortage sets the American pump price.
The FDA approved Pasatru, the first drug shown to reduce both new bone formation and flare-ups in FOP, the ultra-rare disease that turns muscle into a second skeleton. It preserves function, and its value depends on how early the disease is caught.
The Fed's July minutes described elevated inflation and risks skewed to the upside, with the most dissents in a decade. Markets barely moved, because the long end had already priced the warning weeks in advance.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareGartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse ResearchWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.